Quantum Computing Inc. Lands First Pharma Deal with INmune Bio to Accelerate Alzheimer's Drug Discovery

  • Quantum Computing Inc. (QUBT) and INmune Bio Inc. (INMB) announced a collaboration on October 14, 2026, to apply quantum optimization and AI to advance Alzheimer's drug research.
  • The partnership combines INmune Bio's clinical data with QCi's Dirac-3S quantum optimization machine to identify new treatment indications and biomarkers for XPro1595.
  • This marks QCi's first commercial customer in the pharmaceutical and biotechnology markets.
  • The agreement includes options for additional work as INmune Bio advances its clinical development programs.

This collaboration represents a strategic milestone for Quantum Computing Inc. as it enters the pharmaceutical sector, leveraging its quantum optimization technology to tackle complex biomedical data. For INmune Bio, the partnership offers a novel approach to evaluating the broader potential of its XPro1595 platform, potentially accelerating drug development in neurological and rare diseases. The deal underscores the growing intersection of quantum computing and AI in biotechnology, where advanced computational tools are being deployed to enhance drug discovery and clinical research.

Quantum Value Proposition
How QCi's quantum optimization will compare against conventional statistical and machine-learning methods in identifying new treatment indications.
Market Expansion
Whether this collaboration can open a significant new market for QCi in pharmaceutical research.
Regulatory Pathways
The pace at which INmune Bio can leverage quantum computing insights to prioritize and advance new disease indications through clinical trials.